Overall rank by patents
#4,551
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Crispr Therapeutics Ag
USPTO PatentsView assignee record - 77 granted patents across 7 technology areas, active 2020–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
77
Total patents granted
7
CPC technology areas
19.0
Avg claims per patent
-
5-year filing velocity
The verdict
Crispr holds 77 US patents across 7 technology areas, rank #4,551 of 50,000 tracked assignees.
- #4,551
- of 50,000 US assignees by volume
- Top 26%
- by Innovation Score (44.4/100)
- 19.0
- avg claims per patent
Portfolio overview
Crispr Therapeutics Ag has been granted 77 US utility patents between 2020 and 2025, placing Crispr Therapeutics Ag at rank #4,551 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.0 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a Foreign Corporation, Crispr Therapeutics Ag is one of the more focused assignees in the PatentsView dataset. By volume, Crispr sits between Augustine Biomedical + Design, Llc (77 patents, rank #4,547) and Dong-eui University Industry-academic Cooperation Foundation (77 patents, rank #4,555) - the closest US assignees by grant volume. The composite Innovation Score of 44.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 77 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Crispr Therapeutics Ag's 19.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Crispr Therapeutics Ag against peers pursuing similar technology classes.
Who files at Crispr's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Augustine Biomedi…
Augustine Biomedical + Design, LLC
77 patents
- Bizerba SE & KG
BIZERBA SE & CO. KG
77 patents
- Berlin Heart
Berlin Heart GmbH
77 patents
- CHEP Technology P…
CHEP Technology Pty Limited
77 patents
- Camso
Camso Inc.
77 patents
- Cardiovascular Sy…
Cardiovascular Systems, Inc.
77 patents
- Credo Technology…
Credo Technology Group Limited
77 patents
- Dong-eui Universi…
DONG-EUI UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
77 patents
- Crispr Therapeuti… ◀
CRISPR THERAPEUTICS AG
77 patents
What this shows Crispr holds 77 patents at rank #4,551, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Crispr
By rank, the assignees closest to #4,551 in granted patent volume.
- Augustine Biomedical + Design, Llc #4,547 · 77 patents
- Bizerba SE & Co. KG #4,548 · 77 patents
- Berlin Heart Gmbh #4,549 · 77 patents
- CHEP Technology Pty Limited #4,550 · 77 patents
- Camso Inc. #4,552 · 77 patents
- Cardiovascular Systems, Inc. #4,553 · 77 patents
- Credo Technology Group Limited #4,554 · 77 patents
- Dong-eui University Industry-academic Cooperation Foundation #4,555 · 77 patents
Leaders in C12N (Microorganisms OR Enzymes)
Other assignees with the most granted patents in Crispr's primary technology class.
- Monsanto Technology Llc 1,335 in class
- The Regents Of The University Of California 1,161 in class
- Novozymes A/s 656 in class
- Immatics Biotechnologies Gmbh 647 in class
- Pioneer Hi-bred International, Inc. 623 in class
- President And Fellows Of Harvard College 594 in class
- Massachusetts Institute Of Technology 541 in class
- The Trustees Of The University Of Pennsylvania 537 in class
Crispr's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
44 Top 26% higher than 74% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 6 | 7.8% |
| 2021 | 21 | 27.3% |
| 2022 | 12 | 15.6% |
| 2023 | 14 | 18.2% |
| 2024 | 9 | 11.7% |
| 2025 | 15 | 19.5% |
Which technologies does Crispr Therapeutics Ag patent most?
Top 7 of 7 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Frequently Asked Questions
How many patents does Crispr Therapeutics Ag hold?
Crispr Therapeutics Ag holds 77 US granted patents filed between 2020 and 2025, spanning 7 technology areas.
What is Crispr Therapeutics Ag's Innovation Score?
Crispr Therapeutics Ag has an Innovation Score of 44.4 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Crispr Therapeutics Ag focus on?
Crispr Therapeutics Ag's top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 75 patents. The company has filed patents in 7 CPC subclasses total.
Is Crispr Therapeutics Ag's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Crispr Therapeutics Ag.
What does claim depth mean for Crispr Therapeutics Ag's patents?
Crispr Therapeutics Ag's patents average 19.0 claims each. This falls within the standard range, providing solid legal coverage.
How is the Crispr Therapeutics Ag patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Crispr's 77 grants land it in the top 26% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Crispr ranks #4,551 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.